Algorae Pharmaceuticals

Algorae Pharmaceuticals is an Australian clinical-stage pharmaceutical company that integrates artificial intelligence with drug development to address unmet medical needs. The company utilizes its proprietary AlgoraeOS platform, developed in collaboration with the University of New South Wales, to identify novel synergistic drug combinations, often involving cannabinoids and off-patent medications. Its lead candidates include AI-116 for dementia and AI-168 for cardiovascular conditions, alongside NTCELL, an encapsulated cell therapy for Parkinson's disease. Through its subsidiary AlgoraeRx, the company also engages in the commercial distribution of generic pharmaceuticals, such as the oncology drug capecitabine. Algorae is publicly listed on the Australian Securities Exchange (ASX: 1AI) and maintains research partnerships with leading institutions like the Peter MacCallum Cancer Centre and Monash University.